Altamira Therapeutics reports successful outcomes for Bentrio nasal spray in NASAR clinical trial
Altamira Therapeutics Ltd. (Nasdaq:CYTO), a leading innovator in RNA delivery technology for non-liver targets, has achieved significant milestones in its recent NASAR clinical trial for Bentrio nasal spray, used in the treatment of seasonal allergic rhinitis (SAR). The trial’s highlights were notably published in video format on the social media channels of Allergy, a top-tier […]